All adverse outcomes were of mild or moderate severity, and no significant trends were observed on the basis of LVEF status. The most common adverse events were hypotension (33%-36.4%), arrhythmia ...

Medical device maker Abbott Laboratories is nearing a potential takeover of cancer test maker Exact Sciences Corp , Bloomberg ...

Gastrointestinal procedures continue to dominate the ASC landscape in 2025, driven by increased screening demand, younger-onset colorectal cancer and ongoing migration of cases out of hospitals. All ...

As screening guidelines evolve and GI care increasingly shifts to outpatient settings, ASCs are seeing significant growth in colonoscopy volume. Here are ten developments shaping that trend: ...

Scientists have created swallowable microsphere “pills” packed with engineered bacteria that can detect signs of gut disease, ...

Move over, colonoscopies—researchers report in ACS Sensors that they've developed a sensor made of tiny microspheres packed ...

Chinese researchers have developed a new sensor made of tiny microspheres packed with blood-sensing bacteria that detect ...

Approximately 20% of new lung cancer diagnoses occur in nonsmokers in the U.S., according to The Ohio State University ...

Madison, Wisconsin-based Exact Sciences develops cancer screening and diagnostic tests. Its portfolio includes established brands like Cologuard and Oncotype Dx, alongside the Cancerguard test for ...

Swapping colonoscopies for swallowing a pill packed with bacteria that can read the condition of our gut could revolutionize ...

Your primary care provider is more than just your annual stop for routine checkups. They're also the central hub for coordinating your health care, from specialist visits to follow-up testing ...